Tirzepatide vs AOD-9604

A comprehensive, data-driven comparison of Tirzepatide (Mounjaro) and AOD-9604 (Advanced Obesity Drug). Compare efficacy, side effects, costs, FDA approval status, and clinical evidence to make an informed decision.

Tirzepatide
FDA Approved
Type 2 diabetes, chronic weight management, and obstructive sleep apnea
Evidence
High
Avg. Weight Loss22.5%
Monthly Cost$1,100 - $1,100/mo
DosingWeekly
ManufacturerEli Lilly
AOD-9604
Phase 2 (failed; reclassification pending)
Fat loss and metabolism enhancement
Evidence
Low
Monthly Cost$30 - $60/mo
DosingDaily

Side-by-Side Comparison

PropertyTirzepatide
Mounjaro, Zepbound
AOD-9604
Advanced Obesity Drug, Tyr-hGH Fragment 176-191
FDA Status
FDA Approved
Phase 2 (failed; reclassification pending)
Category
Weight Loss
Weight Loss
Primary Use
Type 2 diabetes, chronic weight management, and obstructive sleep apnea
Fat loss and metabolism enhancement
Weight Loss %
22.5%
N/A
Monthly Cost
$1,100 - $1,100/mo
$30 - $60/mo
Administration
Subcutaneous injection
Subcutaneous injection
Typical Dose
15mg weekly (max dose)
300mcg daily
Frequency
Weekly
Daily
Mechanism

Dual GIP/GLP-1 receptor agonist that enhances insulin secretion, reduces glucagon, slows gastric emptying, and decreases appetite

Modified fragment of human growth hormone (amino acids 176-191) that stimulates lipolysis without affecting blood sugar or IGF-1

Common Side Effects
  • Nausea
  • Diarrhea
  • Decreased appetite
  • Vomiting
  • +3 more
  • Injection site reactions
  • Headache
  • Chest tightness (rare)
Serious Side Effects
  • Pancreatitis
  • Hypoglycemia
  • Acute gallbladder disease
  • Hypersensitivity reactions
  • +1 more
  • Unknown long-term effects
  • Potential interactions with growth hormone pathways
Evidence Quality
High
Low
Clinical Trial Phase
Approved
Phase 2

Key Differences

  • 1Tirzepatide is FDA-approved, while AOD-9604 is currently phase 2 (failed; reclassification pending).
  • 2Tirzepatide has clinical weight loss data (22.5%), while AOD-9604 is not primarily indicated for weight loss.
  • 3AOD-9604 is generally more affordable ($30 - $60/mo) compared to Tirzepatide ($1,100 - $1,100/mo).
  • 4Tirzepatide is dosed weekly, while AOD-9604 is daily.
  • 5Tirzepatide has high-quality evidence, while AOD-9604 has low-quality evidence.

Which Is Better For...

TI

Tirzepatide

Those seeking an FDA-approved treatment with established safety data

AO

AOD-9604

More budget-friendly option with lower monthly costs

TI

Tirzepatide

More convenient dosing schedule (weekly)

AO

AOD-9604

Fewer commonly reported side effects

TI

Tirzepatide

Stronger clinical evidence base to support its use

Cost Comparison

PeptideMonthly Cost RangeFDA StatusManufacturer
Tirzepatide$1,100 - $1,100/mo
FDA Approved
Eli Lilly
AOD-9604$30 - $60/mo
Phase 2 (failed; reclassification pending)
Various research labs

Prices are estimated monthly costs and may vary based on pharmacy, insurance coverage, and manufacturer assistance programs. Costs for non-FDA-approved peptides reflect research compound pricing.

Frequently Asked Questions

What is the main difference between Tirzepatide and AOD-9604?

Tirzepatide works via Dual GIP/GLP-1 receptor agonist that enhances insulin secretion, reduces glucagon, slows gastric. AOD-9604 works via Modified fragment of human growth hormone (amino acids 176-191) that stimulates lipolysis. They differ in FDA approval status, efficacy data, and cost.

Which is more effective for weight loss, Tirzepatide or AOD-9604?

Tirzepatide has demonstrated 22.5% average weight loss in clinical trials. AOD-9604 is not primarily used for weight loss.

How much does Tirzepatide cost compared to AOD-9604?

Tirzepatide typically costs $1,100 - $1,100/mo, while AOD-9604 costs $30 - $60/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.

Are Tirzepatide and AOD-9604 FDA approved?

Tirzepatide is FDA-approved. AOD-9604 is not FDA-approved (Phase 2 (failed; reclassification pending)). FDA approval indicates the treatment has met rigorous safety and efficacy standards.

What are the side effects of Tirzepatide vs AOD-9604?

Common side effects of Tirzepatide include Nausea, Diarrhea, Decreased appetite. Common side effects of AOD-9604 include Injection site reactions, Headache, Chest tightness (rare). Always consult a healthcare provider about potential side effects.

Can I switch from Tirzepatide to AOD-9604?

Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.

Learn More

Tirzepatide Full Profile
Type 2 diabetes, chronic weight management, and obstructive sleep apnea

Tirzepatide is a dual-action peptide approved by the FDA as Mounjaro for type 2 diabetes and Zepbound for weight management. In December 2024, Zepbound became the first and only medication approved fo...

View Full Tirzepatide Guide
AOD-9604 Full Profile
Fat loss and metabolism enhancement

AOD-9604 is a modified peptide fragment of the C-terminus of human growth hormone (amino acids 176-191). It was designed to retain the fat-burning properties of HGH while avoiding effects on blood sug...

View Full AOD-9604 Guide

Other Popular Comparisons

Medical Disclaimer

The information provided on this page is for educational and informational purposes only and does not constitute medical advice. This comparison between Tirzepatide and AOD-9604 should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary significantly. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment.